本帖最后由 老马 于 2013-3-13 13:43 编辑
, |+ ?3 i3 h+ t7 t' L& C
2 F) C7 m% K2 ~; W健择(吉西他滨)+顺铂+阿瓦斯汀
0 d% X% _- d+ f) m& m Gemzar +Cisplatin + Avastin
: p& P; x! I& H4 T2 Y0 phttp://annonc.oxfordjournals.org/content/21/9/1804.full
- d/ r1 T3 G6 T+ yOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) e& j+ v# T4 V3 @Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 7 J2 D% J t/ R" n i1 }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - \+ B* N e9 V+ D$ |' S/ E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 905)
* @9 F$ d3 Y# v$ }6 m
华为网盘附件:
. L9 Y9 I/ E; S+ g; H0 V2 w& t! u【华为网盘】ava.JPG
2 X+ E# h c6 r" F" R* ~ |